Ifih1 Related Type 1 Interferonopathy Cn377548
A rare genetic disorder causing excessive type 1 interferon production, leading to immune system overactivation. It typically presents in childhood and requires immunosuppressive therapy under specialist care.
Key facts at a glance
- ICD-10
- R69
- ICD-11
- MA00.0
- Body system
- immunologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(immunologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Recurrent fever episodes
(systemic)Chilblain lupus-like skin lesions
(integumentary)Neurodevelopmental delay
(neurologic)Autoimmune hepatitis
(hepatobiliary)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
JAK Inhibitor Therapy
Janus kinase inhibitors block interferon signaling downstream of IFIH1 gain-of-function mutations. This addresses the underlying molecular pathology by interrupting the excessive type I interferon response characteristic of this condition.
Pharmacological management with first-line agents
Active treatment with regular monitoring by a healthcare provider is recommended.
High-Dose Corticosteroid Therapy
Systemic corticosteroids provide broad anti-inflammatory effects to control systemic manifestations of interferonopathy. Gradual tapering based on clinical response and inflammatory markers.
Additional treatment options
Anti-IFN-alpha Monoclonal Antibodies
Monoclonal antibodies targeting interferon-alpha can neutralize the excess cytokine production. Reserved for cases refractory to standard JAK inhibitor therapy.
medicationInterferon Signature and Disease Activity Monitoring
Regular assessment of interferon-stimulated gene expression signatures to track disease activity. Inflammatory markers and organ-specific evaluations guide treatment decisions.
monitoringAnti-Inflammatory Lifestyle Modifications
Anti-inflammatory diet rich in omega-3 fatty acids, avoidance of pro-inflammatory foods, and stress reduction techniques. Adequate sleep and smoking cessation support overall immune regulation.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Ifih1 Related Type 1 Interferonopathy Cn377548?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Ifih1 Related Type 1 Interferonopathy Cn377548. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy